Chronic Reflux and Barrett''s Esophagus: The Cancer Risk Hiding in Heartburn
Heartburn is so common that most people stop noticing it. A nightly antacid, a wedge pillow, a food you have quietly given up. The relief is real, so the story feels closed. What the relief does not tell you is what years of acid have been doing to the lining of the esophagus underneath. In a minority of people, that lining quietly changes into something precancerous, and the only way to know is to look. Catching that change early, and then watching it over years instead of guessing, is exactly the kind of problem Healz was built to hold.
This is not a reason to panic about heartburn. Most reflux never leads anywhere, and most of the precancerous change that does appear never becomes cancer. But the path from chronic reflux to esophageal cancer is real, it is gradual, and it is one of the few cancers with a clear, watchable warning sign. Understanding that sign is how you stay ahead of it.
What years of reflux actually do to the esophagus
The esophagus is normally lined with flat squamous cells that are not built to sit in acid. When stomach contents wash up repeatedly, as they do in long-standing gastroesophageal reflux disease (GERD), that lining can adapt by swapping itself out for a sturdier, intestine-like type of cell. Pathologists call this intestinal metaplasia, and when it appears in the esophagus it is named Barrett's esophagus.
The American College of Gastroenterology defines Barrett's as at least one centimeter of columnar-lined esophagus with intestinal metaplasia confirmed on biopsy. That last part matters. Barrett's is not something a doctor can diagnose by symptoms or by the look of the esophagus alone. It takes an endoscopy, a tissue sample, and a pathologist reading the cells. The cell change itself often causes no new symptoms at all, which is why it hides so well behind ordinary heartburn.
Ask Healz.
One chat instead of ten apps. 1M+ rare cases checked. The root cause, not the label. Private.
Barrett's matters for one reason: it is the only known precursor to esophageal adenocarcinoma, the type of esophageal cancer that has risen sharply in Western countries alongside reflux and obesity. The lining does not jump straight to cancer. It moves through steps, and each step is something a pathologist can see and grade.
Most Barrett's never becomes cancer
This is the part that gets lost in the fear. Having Barrett's esophagus is not having cancer, and for most people it never will be. Roughly 2% of adults have Barrett's, and the large majority live with it for the rest of their lives without it progressing.
The numbers are reassuring when you look at them plainly. Nondysplastic Barrett's, the flat, no-dysplasia form that most people have, carries an annual risk of progressing to esophageal adenocarcinoma of only about 0.1% to 0.5% per year, per StatPearls and the American Academy of Family Physicians. Fewer than 5% of people with Barrett's ever develop esophageal cancer. There is even evidence that the longer your Barrett's stays flat and nondysplastic across repeat endoscopies, the lower your future risk becomes.
So why watch it at all? Because that small annual risk compounds over decades, and because the people who do progress are worth catching before the change becomes cancer rather than after. Surveillance is not treatment for a disease you have. It is a way of making sure you are in the majority that stays stable, and of acting fast if you are not.
Dysplasia is the real dividing line
The word that decides everything on a Barrett's biopsy is dysplasia, meaning how abnormal the cells look under the microscope. The lining is graded along a path: no dysplasia, then low-grade dysplasia, then high-grade dysplasia, and only then adenocarcinoma. Each step up carries a higher chance of moving further, which is why the grade, not the mere presence of Barrett's, sets the plan.
The jump in risk is steep. Where nondysplastic Barrett's sits near half a percent a year, low-grade and high-grade dysplasia carry substantially higher yearly progression rates in the published literature, which is why they trigger closer follow-up or active treatment rather than watchful waiting. For high-grade dysplasia the usual path is endoscopic eradication therapy, such as radiofrequency ablation, which trials have shown reduces progression to cancer.
Grading is also where second opinions earn their place. Dysplasia is genuinely hard to read, and the ACG recommends that dysplasia of any grade be confirmed by a second gastrointestinal pathologist before it drives a treatment decision. If you want to understand what the pathologist actually wrote, it helps to know how to read a biopsy result and, more broadly, how to read your pathology report, because the difference between low-grade and high-grade on that page can change your next year of care.
Who should actually be screened
Not everyone with heartburn needs an endoscopy, and screening the whole population would find far more harmless findings than dangerous ones. The guidelines aim the camera at the people whose risk is genuinely elevated.
The ACG suggests a single screening endoscopy for people with chronic GERD symptoms who also carry three or more additional risk factors for Barrett's: male sex, age over 50, white race, tobacco use, obesity, and a first-degree family history of Barrett's or esophageal adenocarcinoma. The idea is that chronic reflux plus a stack of risk factors is where Barrett's is common enough to be worth looking for.
Once Barrett's is found, the follow-up interval is set by what the biopsies show. For nondysplastic Barrett's, the ACG ties surveillance to segment length: segments of 3 centimeters or longer are typically rechecked around every three years, and shorter segments under 3 centimeters around every five years. Dysplasia shortens those intervals sharply or moves you to treatment. The point is that the interval is not a fixed rule you memorize once. It changes as your grade and segment change, which is precisely why keeping the whole timeline in view matters so much.
How Healz keeps a decade of endoscopies in one view
A Barrett's diagnosis is not one appointment. It is a decade of endoscopies, biopsies, grades, and segment lengths that only mean something when you can line them up side by side. Healz is equipped with memory, and it does three things by design: it holds every endoscopy report and biopsy you upload, it tracks your dysplasia grade and surveillance interval over time, and it connects those results so a slow drift from nondysplastic to low-grade stands out as a trend instead of a number lost between visits years apart.
That memory works alongside the rest of the case. Healz is equipped with root-cause technology, so it cross-checks your case against 1M+ rare cases and drills past the label to what is actually driving the change rather than stopping at the word Barrett's. Frontier AI reads the actual document, so uploading a pathology report gives you a pathology report ai that puts the grade, the segment length, and your reflux history in one chat instead of ten apps. For anyone weighing a Barrett's or early esophageal finding, that is what an ai for cancer second opinion looks like in practice: your whole record read together, not a fresh reading each visit. When you want a human in the loop, you can bring a board-certified doctor into the same chat for a second opinion.
Frequently asked questions
- Does Barrett's esophagus mean I will get cancer?
No. Barrett's is a precancerous change, not cancer, and most people with it never develop esophageal cancer. Nondysplastic Barrett's progresses to adenocarcinoma at only about 0.1% to 0.5% per year, and fewer than 5% of people with Barrett's ever get esophageal cancer. Surveillance exists to catch the small minority that does change, not because progression is expected.
- What is the difference between low-grade and high-grade dysplasia?
Both mean the Barrett's cells look abnormal, but high-grade is closer to cancer and carries a much higher yearly risk of progressing. Low-grade dysplasia usually means closer surveillance or the option of ablation, while high-grade dysplasia is typically treated with endoscopic eradication therapy. Because the two are hard to tell apart, the ACG recommends a second GI pathologist confirm any grade before it drives treatment.
- Who should be screened for Barrett's esophagus?
The ACG suggests a one-time screening endoscopy for people with chronic GERD plus three or more added risk factors: male sex, age over 50, white race, tobacco use, obesity, or a first-degree relative with Barrett's or esophageal adenocarcinoma. Chronic heartburn alone in someone without those risk factors usually does not require screening. Ask your doctor where you fall.
- How often do you need an endoscopy if you have Barrett's?
It depends on your biopsy. For nondysplastic Barrett's, the ACG sets surveillance by segment length, roughly every three years for longer segments and every five years for shorter ones. If dysplasia appears, the interval shortens sharply or you move to treatment. The interval is not fixed for life, which is why tracking each result over time matters.
Chronic heartburn is usually nothing, and even Barrett's esophagus is usually not the disaster it sounds like. The risk that matters is the slow, silent one, the change in the lining that only means something when you can see it move across years. That is the difference between reacting to a diagnosis and staying ahead of it, and it is the discipline this kind of case demands.
Written by Healz Team · Filed under Health Insights